research Pili trianguli et canaliculi as a phenotypic subtype in patients with central centrifugal cicatricial alopecia: A scanning electron microscopy study
Hair shaft changes may be linked to CCCA, but their role is unclear.
Search
for
Sort by
Research
630-660 / 1000+ results
research Melatonin Promotes the Development of Secondary Hair Follicles in Adult Cashmere Goats by Activating the Keap1-Nrf2 Signaling Pathway and Inhibiting the Inflammatory Transcription Factors NFκB and AP-1
Melatonin improves cashmere goat hair quality by increasing follicles and reducing skin aging.
research Evaluating cepharanthine analogues as natural drugs against SARS‐CoV‐2
Cepharanthine analogues, especially tetrandrine, show potential for treating COVID-19.
research Central centrifugal cicatricial alopecia: A call for additional literature in the pediatric population
More research is needed on CCCA in children, especially Black and Asian adolescents.
research ‘Ritlecitinib: unveiling hair regrowth for alopecia areata’
Ritlecitinib is the first FDA-approved pill for treating significant hair loss in alopecia areata patients aged 12 and up.
research Effect of Injecting Melatonin Capsules on Growth of Skin Follicle of Longdong Cashmere Goats
Injecting melatonin improves cashmere yield by enhancing fiber growth in goats.
research Assessment of the efficacy and tolerability of a topical formulation containing caffeine and Procapil 3% for improvement of male pattern hair loss
The topical treatment with caffeine and Procapil 3% improved male pattern hair loss and was well tolerated after 12 weeks.
research A multicentre placebo‐controlled clinical trial on the efficacy of oral ciclosporin A in the treatment of canine idiopathic sebaceous adenitis in comparison with conventional topical treatment
Oral ciclosporin A and topical treatments both reduce hair loss and scaling in dogs with sebaceous adenitis, but using both together is most effective.
research 26143 Time to scalp hair, eyebrow, and eyelash improvement in patients with alopecia areata treated with baricitinib in the phase 2 portion of the phase 2/3 BRAVE-AA1 study
Baricitinib helped improve hair, eyebrow, and eyelash growth in alopecia areata patients.
research New product intros (finasteride/tadalafil (new combination); sutimlimab; human SARS-CoV-2 recombinant nanoparticle vaccine, adjuvanted with AS03; bupropion hydrochloride/dextromethorphan hydrobromide (new combination))
research Coumarin derivatives, but not coumarin itself, cause skin irritation via topical delivery
Coumarin derivatives cause skin irritation, but coumarin itself does not.
research Impact of a topical lotion, CG428, on permanent chemotherapy-induced alopecia in breast cancer survivors: a pilot randomized double-blind controlled clinical trial (VOLUME RCT)
The lotion CG428 did not show effectiveness in treating permanent hair loss in breast cancer survivors.
research Cepharanthine: An update of its mode of action, pharmacological properties and medical applications
Cepharanthine is a well-tolerated drug with multiple medical uses, including anti-inflammatory and anti-cancer properties.
research Tofacitinib therapy for children with severe alopecia areata
Tofacitinib may help treat severe childhood alopecia areata, but risks require careful consideration.
research In Vitro and In Vivo Models for the Development of Hair Growth Materials By Regulating the β-Catenin Signaling Pathways
The research found a way to develop hair growth materials by targeting a specific signaling pathway.
research Drug news and therapeutic news
JAK inhibitors help treat some diseases but may increase risks of blood clots and cancer in certain patients.
research SELF-ASSEMBLED CHITOSAN NANOPARTICLES FOR PERCUTANEOUS DELIVERY OF CAFFEINE: PREPARATION, CHARACTERIZATION AND IN VITRO RELEASE STUDIES
Chitosan nanoparticles are promising for sustained caffeine delivery through the skin.
research Chromatographic Methods for the Determination of Aminexil, Pyridoxine, and Niacinamide in a Novel Cosmetic Hair Preparation
Two new methods accurately measure Aminexil, Pyridoxine, and Niacinamide in hair products.
research Successful hair regrowth in a Korean patient with alopecia universalis following tofacitinib treatment
A Korean woman with complete hair loss regrew her hair after taking tofacitinib, with no side effects.
research Effectiveness of Baricitinib on Nail Alopecia Areata: A 48-Week Single-Center Retrospective Study
Baricitinib significantly improves nail and hair symptoms in severe alopecia areata.
research 52709 Patient-Reported Outcomes for Scalp, Eyebrow and Eyelash Hair Loss in Patients with Severe Alopecia Areata Treated with Baricitinib: 152 Week Results from two Phase 3 Clinical Trials
Baricitinib helps long-term hair regrowth in severe alopecia areata patients.
research Epidermal E-Cadherin Dependent β-Catenin Pathway Is Phytochemical Inducible and Accelerates Anagen Hair Cycling
A form of vitamin E promotes hair growth by activating a specific skin pathway.
research Redox-Modulatory and MET-Inhibitory Triad: Synergistic Cytotoxicity of L-cysteine, NAC, and MET Inhibition in Cervical Cancer Cells
Combining L-cysteine, NAC, and a MET inhibitor significantly kills cervical cancer cells.
research 43018 Safety Analysis of Baricitinib in Adult Patients with Severe Alopecia Areata From 2 Randomized Clinical Trials over a Median of 1.6 years and up to 3.6 Years of Exposure
Baricitinib is a safe and effective treatment for severe alopecia areata.
research An excellent response to tofacitinib in a Brazilian adolescent patient with alopecia areata: A case report and a review of the literature
A Brazilian teenager with severe hair loss had total hair regrowth with no side effects after using tofacitinib.
research Distribution of SALT scores by Therapeutic Tesponse in Patients with Severe Alopecia After 52 weeks of Baricitinib Therapy
Baricitinib therapy helped many patients with severe alopecia regrow hair after 52 weeks.
research Baricitinib Provides Sustained, Long-Term Efficacy With Consistent Safety for Up to 5 Years of Treatment in Adults With Severe Alopecia Areata: Final Results From BRAVE-AA1 and BRAVE-AA2
Baricitinib is effective and safe for treating severe alopecia areata for up to 5 years.
research Efficacy of Cetirizine 1% Versus Minoxidil 5% Topical Solution in the Treatment of Male Alopecia: A Randomized, Single-blind Controlled Study
Cetirizine 1% helps hair growth in men with no major side effects, but minoxidil 5% works better.
research Cronkhite–Canada Syndrome With Multiple Mesenteric Lymphadenopathy: A Case Report
Early diagnosis and treatment with corticosteroids can improve outcomes in Cronkhite–Canada syndrome.
research Baricitinib Safety for Events of Special Interest in Populations at Risk: Analysis from Randomised Trial Data Across Rheumatologic and Dermatologic Indications
Baricitinib, a drug for rheumatoid arthritis, atopic dermatitis, and alopecia areata, is generally safe with low risk of major side effects, even in patients with risk factors. It's also effective in promoting hair regrowth in alopecia areata patients.